Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Intravenous Remicade Grows Despite Tough Times

This article was originally published in The Pink Sheet Daily

Executive Summary

Implications for anti-TNFs Humira and Enbrel, which tumbled in the first quarter, are unclear.

You may also be interested in...



With New Crohn's Disease Treatment, China's Hutchison MediPharma Seeks Global Co-development Partner

BEIJING - After reporting "encouraging results" in clinical trials in the U.S. on Crohn's Disease patients treated with an innovative drug developed by the Shanghai-based Hutchison MediPharma, the outfit's chief executive officer said she is seeking a co-development deal with a global partner

With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results

The drug maker also reports rising sales for its dyslipidemia franchise.

With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results

The drug maker also reports rising sales for its dyslipidemia franchise.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel